Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05654493 · ClinicalTrials.gov registry record
Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 65
- Enrollment target
NCT05654493: Completed study, sponsored by Mayo Clinic.
NCT05654493 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05654493 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical outcomes of the Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) after 1 day, 1 week,1 month, 3 months, 6 months and one year of follow-up, with the intent to evaluate the efficacy of using MP-TSCPC to treat glaucoma patients.
Interventions
- DEVICE MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-04-18 |
| Est. Completion | 2023-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05654493
The ClinicalTrials.gov registry entry for NCT05654493 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device is the first listed.
NCT05654493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05654493 about?
NCT05654493 is a clinical study titled "Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients". The purpose of this study is to evaluate the clinical outcomes of the Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) after 1 day, 1 week,1 month, 3 months, 6 months and one year of follow-up, with the intent to evaluate the efficacy of using MP-TSCPC to treat glaucoma patients.
What is the current status of trial NCT05654493?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2022-04-18. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05654493?
The interventions under investigation include: MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device (DEVICE).
Who is sponsoring clinical trial NCT05654493?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.